Newsfeeds - Spark Newswire

4 minute read

Vallon Pharmaceuticals Reports Additional Pharmacokinetic And Pharmacodynamic Data From SEAL Study Of ADAIR

Today, 11:21 PM

Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter

VLON

5 minute read

71 Biggest Movers From Yesterday

By Lisa Levin

Today, 11:21 PM

Gainers

ADXN

2 minute read

12 Health Care Stocks Moving In Tuesday’s Intraday Session

By Benzinga Insights

Today, 11:21 PM

AVDL

4 minute read

60 Biggest Movers From Yesterday

By Lisa Levin

Today, 11:21 PM

Gainers

AGE

2 minute read

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

Today, 11:21 PM

ANPC

3 minute read

26 Stocks Moving in Monday’s Pre-Market Session

By Lisa Levin

Today, 11:21 PM

Gainers ERYTECH Pharma S.A. (NASDAQ: ERYP) shares rose 88.4% to $2.30 in pre-market trading. Erytech Pharma recently announced publication of results from Eryapasse Phase 2 trial as treatment for hypersensitive ALL in the British Journal of Haematology.

ACON

4 minute read

55 Biggest Movers From Friday

By Lisa Levin

Today, 11:21 PM

Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 100.9% to close at $2.27 on Friday. Vallon Pharmaceuticals engaged Ladenburg Thalmann & Co Inc to evaluate strategic alternatives for the Company to maximize shareholder value.

ALVR

2 minute read

Movers

12 Health Care Stocks Moving In Friday’s After-Market Session

By Benzinga Insights

Today, 11:21 PM

Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) stock moved upwards by 16.8% to $1.32 during Friday's after-market session. The company's market cap stands at $37.0 million.

AGRX

3 minute read

The Daily Biotech Pulse: WHO Endorses Pfizer’s Oral COVID Therapy, Vallon Pharma Surges On Strategic Review, Novavax Starts Dosing In Adolescents COVID Booster Trial

By Vandana Singh

Today, 11:21 PM

Here's a roundup of top developments in the biotech space over the last 24 hours.

GILD

1 minute read

News

UPDATE: Vallon Says Review Process Could Include ‘exploring the potential for a possible merger, business combination, investment into the Company, or a purchase, license or other acquisition of assets.’

By Bill Haddad

Today, 11:21 PM

Ladenburg has been engaged to advise Vallon on the strategic review process, which could include, without limitation, exploring the potential for a possible merger, business combination, investment into the Company, or a

VLON